Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment

Reuters02-02 20:00

Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment

Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646487-en) on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608886573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608886573","market":"nz","top_or_hot":-1,"title":"Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646487-en) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646487-en) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3CPpZd:1","article_id":"2608886573","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608886573","pubTimestamp":1770033636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD  Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4588":"碎股","BK4112":"金融交易所和数据","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","REGN":"再生元制药公司","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4585":"ETF&股票定投概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4139":"生物科技","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC"},"translate_title":"再生元公布EYLEA HD治疗视网膜疾病的积极3期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"REGN":0.9},"content_text":"Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment\n    \n\n        Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646487-en) on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608886573","isCrawlerRequest":true}